Inhibition of human breast cancer cell growth by blockade of the mevalonate-protein prenylation pathway is not prevented by overexpression of cyclin D1

Breast Cancer Research and Treatment

Volumn 67, Issue 1, 2001, Pages 23-33

  Germano, D ^a   Pacilio, C ^a   Cancemi, M ^a   Cicatiello, L ^a   Altucci, L ^a   Belsito Petrizzi, V ^a   Sperandio, C ^a   Salzano, S ^b   Michalides, R J A M ^c   Taya, Y ^d   Bresciani, F ^a   Weisz, A ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Breast cancer; Cell cycle; Cyclin D1; Estrogen; HMG CoA reductase; Protein prenylation; Retinoblastoma protein; Simvastatin

Indexed keywords

CYCLIN D1; MEVALONIC ACID; SIMVASTATIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER FAMILY; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; CYTOSTASIS; EMBRYO; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MITOGENESIS; NONHUMAN; PRECANCER; PRENYLATION; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ANIMALS; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; CYCLIN D1; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEVALONIC ACID; NEOPLASM PROTEINS; PROTEIN ISOPRENYLATION; RATS; SIMVASTATIN;

EID: 0034899385     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010675310188     Document Type: Article

References (58)

1. Cholesterol inhibition, cancer, and chemotherapy
2. Rational cancer therapy
3. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics
4. CA1A2X-competitive inhibitors of famesyltransferase as anticancer agents
5. Pre-clinical development of farnesyl-transferase inhibitors
6. Regulation of the mevalonate pathway
7. Farnesyltransferase inhibitors: Ras research yields a potential anticancer therapeutic
8. Protein prenylation, et cetera: Signal transduction in two dimensions
9. Synchronization of tumor and normal cells from multiple cell cycles by Lovastatin
10. Effects of isoprenoids on growth of normal human mammary epithelial cells and breast cancer cells in vitro
11. 1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK-1 and -2 MAP kinase activation
12. Anti-carcinogenic activity of simvastatin during the promotion phase of radiation-induced mammary tumorigenesis of rats
13. Reduction of mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis
14. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice
15. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-fas in transgenic mice
16. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
17. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis
18. Lovastatin induces growth inhibition and apoptosis in human malignant glioblastoma cells
19. Lovastatin induces apoptosis by inhibiting mitotic and post-mitotic events in cultured mesangial cells
20. Farnesyl transferase inhibitors induce apoptosis of ras-transformed cells denied substratum attachement
21. Prenyltransferase inhibitors induce apoptosis in proliferating thyroid cells through a p53-independent CrmA-sensitive, and caspase-3-like protease-dependent mechanism
22. Cancer cell cycles
23. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer
24. Cyclin D1 in breast cancer
25. Cyclins and breast cancer
26. Overexpression of cyclin D1 mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions
27. Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancer
28. Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit
29. Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens
30. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression
31. Rb phosphorylation during mitogenic stimulation of G1-arrested human breast cancer cells
32. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2
33. Estrogen stimulates transcription of c-jun protooncogene
34. Structure and expression in L-cells of a cloned H4 histone gene of the mouse
35. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line
36. Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cancer cells occurs in a cell cycle-independent fashion
37. Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21 (WAF1/CIP1) in human prostate carcinoma cells
38. 1 arrest in normal and tumor breast cells in through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53
39. 1 cyclin-dependent kinases
40. Cdk-independent activation of estrogen receptor by cyclin D1
41. Estrogen induce early and timed activation of cyclin-dependent kinases 4, 5 and 6 and increases cyclin messenger ribonucleic acid expression in rat uterus
42. 1 to complete the cell cycle
43. Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for Cdk2 activation and pRb hyperphosphorylation
44. Molecular markers in male breast carcinoma
45. Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast
46. Cyclin D1 amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis
47. Cyclin-D1 expression in node-positive (N+) and node-negative (N-) infiltrating human mammary carcinomas
48. Determination of the prognostic value of cyclin D1 overexpression in breast cancer
49. WAF1/CIP1/SDII in a p53-independent manner
50. Rescue of cyclin D1 deficiency by knockin cyclin E
51. Expression and amplification of cyclin genes in human breast cancer
52. Redundant cyclin overexpression and gene amplification in breast cancer cells
53. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein
54. Regulatory role of mevalonate in the growth of normal and neoplastic human mammary epithelial cells
55. Estrogen-dependent cyclin E-Cdk2 activation through p21 redistribution
56. 1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2
57. c-myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry
58. Kip1 regulated by mitogen-activated protein kinase (MEK 1)